1-4 of 4
betamethasone
Close
Sort by
Journal Articles

The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex

Johan Lund, MD, Sigrid Karstorp, MD, Evren Alici, MD PhD, Astrid Gruber, MD PhD, Birgitta Lauri, MD, Cecilie Blimark, MD PhD, Agneta Swedin, MD PhD, Markus Hansson, MD PhD, Karin Forsberg, MD, Lucia Ahlberg, MD, Carlsson Conny, MD, Anders Waage, MD PhD, Peter Gimsing, Annette Juul Vangsted, MD PhD, Ulf Christian Frølund, MD, Mats Hardling, Ulf-Henrik Mellqvist, MD PhD, Hareth Nahi
Journal: Blood
Blood (2015) 126 (23): 3047.
https://doi.org/10.1182/blood.V126.23.3047.3047
Published: 2015
Journal Articles

Subcutaneous Alemtuzumab Is Safe and Effective for Treatment of Global or Single-Lineage Immune-Mediated Marrow Failure: A Pilot Study.

Antonio M. Risitano, MD, PhD, Carmine Selleri, MD, Bianca Serio, MD, Ludovica Marando, Andrea Camera, MD, Lucio Catalano, MD, Giulia Scalia, PhD, Luigi Del Vecchio, MD, Bruno Rotoli, MD
Journal: Blood
Blood (2007) 110 (11): 1692.
https://doi.org/10.1182/blood.V110.11.1692.1692
Published: 2007
Journal Articles

A High Throughput Seeking Myeloma Therapeutics Identifies Glucocorticoids as Inhibitors of c-Maf-Dependent Transactivation of Cyclin D2.

Xinliang Mao, MD, PhD, A. Keith Stewart, MD, Alessandro Datti, Aaron D. Schimmer, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 3384.
https://doi.org/10.1182/blood.V106.11.3384.3384
Published: 2005
Journal Articles

Autoimmune Hemolytic Anemia in NZB/Bl Mice Treated with the Corticosteroid Drug Betamethasone

T. P. CASEY, M.B., Ch.B.(N.Z.), M.R.C.P., M.R.A.C.P., J. B. HOWIE, M.B., Ch.B.(N.Z.), D.Phil. (Oxon), M.C. Path.
Journal: Blood
Blood (1965) 25 (4): 423–431.
https://doi.org/10.1182/blood.V25.4.423.423
Published: 1965